Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation

NCT00847223 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00847223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00847223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation
Lead sponsor
Lymphoma Study Association
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2007
Completion date
March 31, 2009
Enrollment
11 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma